-
Je něco špatně v tomto záznamu ?
Structural determinants of peptide-dependent TAP1-TAP2 transit passage targeted by viral proteins and altered by cancer-associated mutations
M. Padariya, S. Kote, M. Mayordomo, I. Dapic, J. Alfaro, T. Hupp, R. Fahraeus, U. Kalathiya
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2012
Free Medical Journals
od 2012
PubMed Central
od 2012
Open Access Digital Library
od 2012-01-01
Open Access Digital Library
od 2012-04-01
Open Access Digital Library
od 2012-01-01
Elsevier Open Access Journals
od 2012-04-01
ROAD: Directory of Open Access Scholarly Resources
od 2011
- Publikační typ
- časopisecké články MeSH
The TAP1-TAP2 complex transports antigenic peptide substrates into the endoplasmic reticulum (ER). In ER, the peptides are further processed and loaded on the major histocompatibility class (MHC) I molecules by the peptide loading complex (PLC). The TAP transporters are linked with the PLC; a target for cancers and viral immune evasion. But the mechanisms whereby the cancer-derived mutations in TAP1-TAP2 or viral factors targeting the PLC, interfere peptide transport are only emerging. This study describes that transit of peptides through TAP can take place via two different channels (4 or 8 helices) depending on peptide length and sequence. Molecular dynamics and binding affinity predictions of peptide-transporters demonstrated that smaller peptides (8-10 mers; e.g. AAGIGILTV, SIINFEKL) can transport quickly through the transport tunnel compared to longer peptides (15-mer; e.g. ENPVVHFFKNIVTPR). In line with a regulated and selective peptide transport by TAPs, the immunopeptidome upon IFN-γ treatment in melanoma cells induced the shorter length (9-mer) peptide presentation over MHC-I that exhibit a relatively weak binding affinity with TAP. A conserved distance between N and C terminus residues of the studied peptides in the transport tunnel were reported. Furthermore, by adversely interacting with the TAP transport passage or affecting TAPNBD domains tilt movement, the viral proteins and cancer-derived mutations in TAP1-TAP2 may induce allosteric effects in TAP that block conformation of the tunnel (closed towards ER lumen). Interestingly, some cancer-associated mutations (e.g. TAP1R372Q and TAP2R373H) can specifically interfere with selective transport channels (i.e. for longer-peptides). These results provide a model for how viruses and cancer-associated mutations targeting TAP interfaces can affect MHC-I antigen presentation, and how the IFN-γ pathway alters MHC-I antigen presentation via the kinetics of peptide transport.
Department of Medical Biosciences Building 6M Umeå University 901 85 Umeå Sweden
Institute of Genetics and Cancer University of Edinburgh Edinburgh Scotland EH4 2XR United Kingdom
RECAMO Masaryk Memorial Cancer Institute Zlutykopec 7 65653 Brno Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22001741
- 003
- CZ-PrNML
- 005
- 20220112153710.0
- 007
- ta
- 008
- 220107s2021 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.csbj.2021.09.006 $2 doi
- 035 __
- $a (PubMed)34589184
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Padariya, Monikaben $u International Centre for Cancer Vaccine Science, University of Gdansk, ul. Kładki 24, 80-822 Gdansk, Poland
- 245 10
- $a Structural determinants of peptide-dependent TAP1-TAP2 transit passage targeted by viral proteins and altered by cancer-associated mutations / $c M. Padariya, S. Kote, M. Mayordomo, I. Dapic, J. Alfaro, T. Hupp, R. Fahraeus, U. Kalathiya
- 520 9_
- $a The TAP1-TAP2 complex transports antigenic peptide substrates into the endoplasmic reticulum (ER). In ER, the peptides are further processed and loaded on the major histocompatibility class (MHC) I molecules by the peptide loading complex (PLC). The TAP transporters are linked with the PLC; a target for cancers and viral immune evasion. But the mechanisms whereby the cancer-derived mutations in TAP1-TAP2 or viral factors targeting the PLC, interfere peptide transport are only emerging. This study describes that transit of peptides through TAP can take place via two different channels (4 or 8 helices) depending on peptide length and sequence. Molecular dynamics and binding affinity predictions of peptide-transporters demonstrated that smaller peptides (8-10 mers; e.g. AAGIGILTV, SIINFEKL) can transport quickly through the transport tunnel compared to longer peptides (15-mer; e.g. ENPVVHFFKNIVTPR). In line with a regulated and selective peptide transport by TAPs, the immunopeptidome upon IFN-γ treatment in melanoma cells induced the shorter length (9-mer) peptide presentation over MHC-I that exhibit a relatively weak binding affinity with TAP. A conserved distance between N and C terminus residues of the studied peptides in the transport tunnel were reported. Furthermore, by adversely interacting with the TAP transport passage or affecting TAPNBD domains tilt movement, the viral proteins and cancer-derived mutations in TAP1-TAP2 may induce allosteric effects in TAP that block conformation of the tunnel (closed towards ER lumen). Interestingly, some cancer-associated mutations (e.g. TAP1R372Q and TAP2R373H) can specifically interfere with selective transport channels (i.e. for longer-peptides). These results provide a model for how viruses and cancer-associated mutations targeting TAP interfaces can affect MHC-I antigen presentation, and how the IFN-γ pathway alters MHC-I antigen presentation via the kinetics of peptide transport.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kote, Sachin $u International Centre for Cancer Vaccine Science, University of Gdansk, ul. Kładki 24, 80-822 Gdansk, Poland
- 700 1_
- $a Mayordomo, Marcos $u International Centre for Cancer Vaccine Science, University of Gdansk, ul. Kładki 24, 80-822 Gdansk, Poland
- 700 1_
- $a Dapic, Irena $u International Centre for Cancer Vaccine Science, University of Gdansk, ul. Kładki 24, 80-822 Gdansk, Poland
- 700 1_
- $a Alfaro, Javier $u International Centre for Cancer Vaccine Science, University of Gdansk, ul. Kładki 24, 80-822 Gdansk, Poland $u Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, Scotland EH4 2XR, United Kingdom
- 700 1_
- $a Hupp, Ted $u International Centre for Cancer Vaccine Science, University of Gdansk, ul. Kładki 24, 80-822 Gdansk, Poland $u Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, Scotland EH4 2XR, United Kingdom
- 700 1_
- $a Fahraeus, Robin $u International Centre for Cancer Vaccine Science, University of Gdansk, ul. Kładki 24, 80-822 Gdansk, Poland $u Inserm UMRS1131, Institut de Génétique Moléculaire, Université Paris 7, Hôpital St. Louis, F-75010 Paris, France $u Department of Medical Biosciences, Building 6M, Umeå University, 901 85 Umeå, Sweden $u RECAMO, Masaryk Memorial Cancer Institute, Zlutykopec 7, 65653 Brno, Czech Republic
- 700 1_
- $a Kalathiya, Umesh $u International Centre for Cancer Vaccine Science, University of Gdansk, ul. Kładki 24, 80-822 Gdansk, Poland
- 773 0_
- $w MED00184782 $t Computational and structural biotechnology journal $x 2001-0370 $g Roč. 19, č. - (2021), s. 5072-5091
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34589184 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20220107 $b ABA008
- 991 __
- $a 20220112153706 $b ABA008
- 999 __
- $a ind $b bmc $g 1745597 $s 1152888
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 19 $c - $d 5072-5091 $e 20210909 $i 2001-0370 $m Computational and structural biotechnology journal $n Comput Struct Biotechnol J $x MED00184782
- LZP __
- $a Pubmed-20220107